Merve Gizer
Merve Gizer has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Petek Korkusuz
Hacettepe University
11 shared publications - Selin Önen
METU MEMS Center, Ankara, Turkiye
4 shared publications - Fatima Aerts-Kaya
Department of Stem Cell Sciences, Hacettepe University Graduate School of Health Sciences, Ankara, Turkey
3 shared publications - Özgür Doğuş Erol
Department of Stem Cell Sciences, Graduate School of Health Sciences, Center for Stem Cell Research and Development (PEDİSTEM), Hacettepe University , Ankara, Turkey
3 shared publications - Eda Ciftci
Department of Bioengineering Graduate School of Science and Engineering, Hacettepe University, Beytepe Ankara Türkiye
2 shared publications - Feza Korkusuz
Department of Sports Medicine, Faculty of Medicine, Hacettepe University, Ankara 06230, Türkiye
2 shared publications
Latest Publications
- Open Access
- 8 December 2025
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 51 (3) , 537-545
Effect of Activated Platelet-Rich Plasma on In Vitro Spermatogenesis in Testicular Organoids
Infertility affects 10–20% of couples, and male-related factors contribute to 30–50% of cases. Although testicular organoids (TOs) support in vitro spermatogenesis, one of the most significant limitations of these approaches is the undefined nature of serum and/or xenogenic growth factors used in the culture media. Platelet-rich plasma (PRP) has a regenerative effect on spermatogenesis after testicular damage and maintains the proliferation and function of spermatogonial stem cells (SSCs) in vitro. In this study, prepubertal C57BL/6 testicular cells were cultured with activated PRP using ultra-low attachment and air–liquid interface culture systems. Spermatogenic progression was evaluated at weeks 1, 3, 4, and 6 through histomorphometric and immunohistochemical analyses. In TOs supported with 10% PRP (PRP group), the SSC pool was preserved for 6 weeks, and the number of ID4(+) SSCs was higher than that in TOs supported with 10% knockout serum replacement (KK group) and 5% knockout serum replacement + 5% fetal bovine serum (KF group) at weeks 3, 4, and 6. In the PRP group, the number of SCP3(+) spermatocytes remained constant from weeks 1 to 6 and was higher than that in the KK and KF groups at weeks 4 and 6. In all TOs, ACR(+) round spermatids were observed at week 3, and PRP group had more ACR(+) spermatids than KK group at week 4. The results suggest that activated PRP may serve as a promising culture supplement to support spermatogenesis, although its safety and clinical applicability require further investigation.
- 8 December 2025
- Published by Uludag Universitesi Tip Fakultesi Dergisi in Uludağ Üniversitesi Tıp Fakültesi Dergisi
- Vol. 51 (3) , 537-545
Open AccessEffect of Activated Platelet-Rich Plasma on In Vitro Spermatogenesis in Testicular Organoids
Infertility affects 10–20% of couples, and male-related factors contribute to 30–50% of cases. Although testicular organoids (TOs) support in vitro spermatogenesis, one of the most significant limitations of these approaches is the undefined nature of serum and/or xenogenic growth factors used in the culture media. Platelet-rich plasma (PRP) has a regenerative effect on spermatogenesis after testicular damage and maintains the proliferation and function of spermatogonial stem cells (SSCs) in vitro. In this study, prepubertal C57BL/6 testicular cells were cultured with activated PRP using ultra-low attachment and air–liquid interface culture systems. Spermatogenic progression was evaluated at weeks 1, 3, 4, and 6 through histomorphometric and immunohistochemical analyses. In TOs supported with 10% PRP (PRP group), the SSC pool was preserved for 6 weeks, and the number of ID4(+) SSCs was higher than that in TOs supported with 10% knockout serum replacement (KK group) and 5% knockout serum replacement + 5% fetal bovine serum (KF group) at weeks 3, 4, and 6. In the PRP group, the number of SCP3(+) spermatocytes remained constant from weeks 1 to 6 and was higher than that in the KK and KF groups at weeks 4 and 6. In all TOs, ACR(+) round spermatids were observed at week 3, and PRP group had more ACR(+) spermatids than KK group at week 4. The results suggest that activated PRP may serve as a promising culture supplement to support spermatogenesis, although its safety and clinical applicability require further investigation.
- 11 October 2025
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (1) , 566-578
Assessment of Potential Side Effects Related To RAB27A Gene Therapy in Stem Cells
RAB27A plays an essential role in the regulation of exocytosis and intracellular vesicle trafficking. Loss-of-function mutations in the RAB27A gene cause dysfunctional immune cells and Griscelli Syndrome Type 2 (GS-2), whereas upregulation of RAB27A in cancer cells is associated with a worse prognosis and increased metastasis. Here, we wanted to assess the potential side effects of overexpression of RAB27A in different types of healthy stem cells as preparation for the development of gene therapy for GS-2. Bone marrow mesenchymal stem cells (BM-MSCs) were obtained from GS-2 patients and healthy donors. Healthy murine bone marrow-derived and human cord blood-derived hematopoietic stem/progenitor cells (HSPCs) were transduced with different lentiviral vectors carrying a codon-optimized RAB27A (RAB27Aco) transgene. Cells were used for in vitro functional assays and assessed using flow cytometry, Western Blot and RT-PCR. In vivo transplantation assays in mice were used to assess the effect of RAB27A on stem cell function. Engraftment was assessed using flow cytometry, sections of BM-MSC injection sites were analyzed using histological staining. Overexpression of RAB27A resulted in phenotypic changes in BM-MSCs and decreased colony-forming capacity of HSPCs. Transplantation of RAB27A + stem cells was not associated with any tumorigenesis. Despite high expression of RAB27A in HSPCs before transplantation, RAB27A levels in peripheral blood, bone marrow, and spleen cells remained low, indicating overexpression of RAB27A may have affected the long-term reconstitution potential. Development of gene therapy for GS-2 may require fine-tuning of RAB27A expression but is not likely to be complicated by RAB27A-induced tumorigenesis. Graphical Abstract
- 11 October 2025
- Published by Springer Nature in Stem Cell Reviews and Reports
- Vol. 22 (1) , 566-578
Assessment of Potential Side Effects Related To RAB27A Gene Therapy in Stem Cells
RAB27A plays an essential role in the regulation of exocytosis and intracellular vesicle trafficking. Loss-of-function mutations in the RAB27A gene cause dysfunctional immune cells and Griscelli Syndrome Type 2 (GS-2), whereas upregulation of RAB27A in cancer cells is associated with a worse prognosis and increased metastasis. Here, we wanted to assess the potential side effects of overexpression of RAB27A in different types of healthy stem cells as preparation for the development of gene therapy for GS-2. Bone marrow mesenchymal stem cells (BM-MSCs) were obtained from GS-2 patients and healthy donors. Healthy murine bone marrow-derived and human cord blood-derived hematopoietic stem/progenitor cells (HSPCs) were transduced with different lentiviral vectors carrying a codon-optimized RAB27A (RAB27Aco) transgene. Cells were used for in vitro functional assays and assessed using flow cytometry, Western Blot and RT-PCR. In vivo transplantation assays in mice were used to assess the effect of RAB27A on stem cell function. Engraftment was assessed using flow cytometry, sections of BM-MSC injection sites were analyzed using histological staining. Overexpression of RAB27A resulted in phenotypic changes in BM-MSCs and decreased colony-forming capacity of HSPCs. Transplantation of RAB27A + stem cells was not associated with any tumorigenesis. Despite high expression of RAB27A in HSPCs before transplantation, RAB27A levels in peripheral blood, bone marrow, and spleen cells remained low, indicating overexpression of RAB27A may have affected the long-term reconstitution potential. Development of gene therapy for GS-2 may require fine-tuning of RAB27A expression but is not likely to be complicated by RAB27A-induced tumorigenesis. Graphical Abstract
- Open Access
- 12 March 2025
- Published by Springer Nature in Biological Research
- Vol. 58 (1) , 13
Endocannabinoid system upregulates the enrichment and differentiation of human iPSC- derived spermatogonial stem cells via CB2R agonism
Background: Male factor infertility (MFI) is responsible for 50% of infertility cases and in 15% of the cases sperm is absent due to germ cell aplasia. Human induced pluripotent stem cell (hiPSC)-derived spermatogonial stem cells (hSSCs) could serve as an autologous germ cell source for MFI in patients with an insufficient sperm yield for assisted reproductive technology (ART). The endocannabinoid system (ECS) has been implicated to play a role in mouse embryonic stem cells (mESCs) and the human testicular environment. However, the contribution of the ECS in hiPSCs and hiPSC-derived hSSCs is currently unknown. Here, we aimed to assess whether hiPSCs and hiPSC-derived hSSCs are regulated by components of the ECS and whether manipulation of the ECS could increase the yield of hiPSC-derived SSCs and serve as an autologous cell-based source for treatment of MFI. Methods: We reprogrammed human dermal fibroblasts (hDFs) to hiPSCs, induced differentiation of hSSC from hiPSCs and evaluated the presence of ECS ligands (AEA, 2-AG) by LC/MS, receptors (CB1R, CB2R, TRPV1, GPR55) by qPCR, flow cytometry and immunofluorescent labeling. We then examined the efficacy of endogenous and synthetic selective ligands (ACPA, CB65, CSP, ML184) on proliferation of hiPSCs using real-time cell analysis (RTCA) and assessed the effects of on CB2R agonism on hiPSC pluripotency and differentiation to hSSCs. Results: hiPSCs from hDFs expressed the pluripotency markers OCT4, SOX2, NANOG, SSEA4 and TRA-1-60; and could be differentiated into ID4+, PLZF + hSSCs. hiPSCs and hiPSC-derived hSSCs secreted AEA and 2-AG at 10− 10 − 10− 9 M levels. Broad expression of all ECS receptors was observed in both hiPSCs and hiPSC-derived hSSCs, with a higher CB2R expression in hSSCs in comparison to hiPSCs. CB2R agonist CB65 promoted proliferation and differentiation of hiPSCs to hiPSC-hSSCs in comparison to AEA, 2-AG, ACPA, CSP and ML184. The EC50 of CB65 was determined to be 2.092 × 10− 8 M for support of pluripotency and preservation of stemness on hiPSCs from 78 h. CB65 stimulation at EC50 also increased the yield of ID4 + hSSCs, PLZF + SSPCs and SCP3 + spermatocytes from day 10 to 12. Conclusions: We demonstrated here for the first time that stimulation of CB2R results in an increased yield of hiPSCs and hiPSC-derived hSSCs. CB65 is a potent CB2R agonist that can be used to increase the yield of hiPSC-derived hSSCs offering an alternative source of autologous male germ cells for patients with MFI. Increasing the male germ/stem cell pool by CB65 supplementation could be part of the ART-associated protocols in MFI patients with complete germ cell aplasia.
- 12 March 2025
- Published by Springer Nature in Biological Research
- Vol. 58 (1) , 13
Open AccessEndocannabinoid system upregulates the enrichment and differentiation of human iPSC- derived spermatogonial stem cells via CB2R agonism
Background: Male factor infertility (MFI) is responsible for 50% of infertility cases and in 15% of the cases sperm is absent due to germ cell aplasia. Human induced pluripotent stem cell (hiPSC)-derived spermatogonial stem cells (hSSCs) could serve as an autologous germ cell source for MFI in patients with an insufficient sperm yield for assisted reproductive technology (ART). The endocannabinoid system (ECS) has been implicated to play a role in mouse embryonic stem cells (mESCs) and the human testicular environment. However, the contribution of the ECS in hiPSCs and hiPSC-derived hSSCs is currently unknown. Here, we aimed to assess whether hiPSCs and hiPSC-derived hSSCs are regulated by components of the ECS and whether manipulation of the ECS could increase the yield of hiPSC-derived SSCs and serve as an autologous cell-based source for treatment of MFI. Methods: We reprogrammed human dermal fibroblasts (hDFs) to hiPSCs, induced differentiation of hSSC from hiPSCs and evaluated the presence of ECS ligands (AEA, 2-AG) by LC/MS, receptors (CB1R, CB2R, TRPV1, GPR55) by qPCR, flow cytometry and immunofluorescent labeling. We then examined the efficacy of endogenous and synthetic selective ligands (ACPA, CB65, CSP, ML184) on proliferation of hiPSCs using real-time cell analysis (RTCA) and assessed the effects of on CB2R agonism on hiPSC pluripotency and differentiation to hSSCs. Results: hiPSCs from hDFs expressed the pluripotency markers OCT4, SOX2, NANOG, SSEA4 and TRA-1-60; and could be differentiated into ID4+, PLZF + hSSCs. hiPSCs and hiPSC-derived hSSCs secreted AEA and 2-AG at 10− 10 − 10− 9 M levels. Broad expression of all ECS receptors was observed in both hiPSCs and hiPSC-derived hSSCs, with a higher CB2R expression in hSSCs in comparison to hiPSCs. CB2R agonist CB65 promoted proliferation and differentiation of hiPSCs to hiPSC-hSSCs in comparison to AEA, 2-AG, ACPA, CSP and ML184. The EC50 of CB65 was determined to be 2.092 × 10− 8 M for support of pluripotency and preservation of stemness on hiPSCs from 78 h. CB65 stimulation at EC50 also increased the yield of ID4 + hSSCs, PLZF + SSPCs and SCP3 + spermatocytes from day 10 to 12. Conclusions: We demonstrated here for the first time that stimulation of CB2R results in an increased yield of hiPSCs and hiPSC-derived hSSCs. CB65 is a potent CB2R agonist that can be used to increase the yield of hiPSC-derived hSSCs offering an alternative source of autologous male germ cells for patients with MFI. Increasing the male germ/stem cell pool by CB65 supplementation could be part of the ART-associated protocols in MFI patients with complete germ cell aplasia.
- Open Access
- 20 December 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 48 (6) , 379-389
Cannabinoid receptor ligands modulate fibrosis and inflammation in idiopathicpulmonary fibrosis: a preliminary study
Background/aim: There is no specific pharmacological treatment regimen for idiopathic pulmonary fibrosis (IPF). Therefore, new anti-inflammatory therapeutic strategies are needed. Cannabinoids (CBs) that are known for their inflammation-modulating and anti-fibrotic effects may be potential medication candidates for the treatment of IPF. Our aim is to evaluate the inflammation-modulating and anti-fibrotic effects of CB receptor (CBR) agonists and antagonists in lipopolysaccharide (LPS) stimulated human lung healthy fibroblast, epithelial cells, IPF fibroblast cells and monocytes.Materials and methods: We detected CBRs in the human lung healthy (LL24) and IPF fibroblast cells (LL29), epithelial cells (A549) and monocytes (THP-1) by flow cytometry (FC). We determined TGF-β1, IL-8 and TNF-α inflammatory cytokines in the LL24, LL29, A549 and THP-1 cell culture supernatants on day 1 and 5 by ELISA. We evaluated the cell viability in LL24, LL29 and A549 cells on days 1, 3 and 5 spectrophotometrically. We detected collagen Type I (ColI) production in the LL24 and LL29 cell culture supernatants on days 1, 3 and 5 by ELISA.Results: LL24, LL29, A549 and THP-1 cells presented CB1 (CB1R) and CB2 (CB2R) receptors. CB1R and CB2R agonists WIN55,212-2 and JWH015 inhibited fibroblastic and epithelial cell proliferation on day 5. TGF-β1 and TNF-α release increased, while IL-8 release decreased in LL24, LL29, A549 and THP-1 cells in response to administration of WIN55,212-2 and JWH015 at 10-2 mM concentration. CB1R and CB2R antagonists AM251 and AM630, respectively, did not block agonistic responses, suggesting a non-classical CBR mediated pathway. CB2R agonist JWH015 decreased ColI expression from IPF lung fibroblasts LL29 on day 3.Conclusion: These results suggest that CB signaling plays a regulatory role in the progress of pulmonary inflammation and fibrosis and via CBR activation that may offer a potential pharmacological tool for developing antifibrosis therapies.
- 20 December 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF BIOLOGY
- Vol. 48 (6) , 379-389
Open AccessCannabinoid receptor ligands modulate fibrosis and inflammation in idiopathicpulmonary fibrosis: a preliminary study
Background/aim: There is no specific pharmacological treatment regimen for idiopathic pulmonary fibrosis (IPF). Therefore, new anti-inflammatory therapeutic strategies are needed. Cannabinoids (CBs) that are known for their inflammation-modulating and anti-fibrotic effects may be potential medication candidates for the treatment of IPF. Our aim is to evaluate the inflammation-modulating and anti-fibrotic effects of CB receptor (CBR) agonists and antagonists in lipopolysaccharide (LPS) stimulated human lung healthy fibroblast, epithelial cells, IPF fibroblast cells and monocytes.Materials and methods: We detected CBRs in the human lung healthy (LL24) and IPF fibroblast cells (LL29), epithelial cells (A549) and monocytes (THP-1) by flow cytometry (FC). We determined TGF-β1, IL-8 and TNF-α inflammatory cytokines in the LL24, LL29, A549 and THP-1 cell culture supernatants on day 1 and 5 by ELISA. We evaluated the cell viability in LL24, LL29 and A549 cells on days 1, 3 and 5 spectrophotometrically. We detected collagen Type I (ColI) production in the LL24 and LL29 cell culture supernatants on days 1, 3 and 5 by ELISA.Results: LL24, LL29, A549 and THP-1 cells presented CB1 (CB1R) and CB2 (CB2R) receptors. CB1R and CB2R agonists WIN55,212-2 and JWH015 inhibited fibroblastic and epithelial cell proliferation on day 5. TGF-β1 and TNF-α release increased, while IL-8 release decreased in LL24, LL29, A549 and THP-1 cells in response to administration of WIN55,212-2 and JWH015 at 10-2 mM concentration. CB1R and CB2R antagonists AM251 and AM630, respectively, did not block agonistic responses, suggesting a non-classical CBR mediated pathway. CB2R agonist JWH015 decreased ColI expression from IPF lung fibroblasts LL29 on day 3.Conclusion: These results suggest that CB signaling plays a regulatory role in the progress of pulmonary inflammation and fibrosis and via CBR activation that may offer a potential pharmacological tool for developing antifibrosis therapies.
- Open Access
- 14 May 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (5) , e13821
Bone marrow mesenchymal stromal cells support regeneration of intestinal damage in a colitis mouse model, independent of their CXCR4 expression
Inflammatory bowel disease (IBD) is characterized by a chronically dysregulated immune response in the gastrointestinal tract. Bone marrow multipotent mesenchymal stromal cells have an important immunomodulatory function and support regeneration of inflamed tissue by secretion of soluble factors as well as through direct local differentiation. CXCR4 is the receptor for CXCL12 (SDF‐1, stromal‐derived factor‐1) and has been shown to be the main chemokine receptor, required for homing of MSCs. Increased expression of CXCL12 by inflamed intestinal tissue causes constitutive inflammation by attracting lymphocytes but can also be used to direct MSCs to sites of injury/inflammation. Trypsin is typically used to dissociate MSCs into single‐cell suspensions but has also been shown to digest surface CXCR4. Here, we assessed the regenerative effects of CXCR4high and CXCR4low MSCs in an immune‐deficient mouse model of DSS‐induced colitis. We found that transplantation of MSCs resulted in clinical improvement and histological recovery of intestinal epithelium. In contrary to our expectations, the levels of CXCR4 on transplanted MSCs did not affect their regenerative supporting potential, indicating that paracrine effects of MSCs may be largely responsible for their regenerative/protective effects.
- 14 May 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (5) , e13821
Open AccessBone marrow mesenchymal stromal cells support regeneration of intestinal damage in a colitis mouse model, independent of their CXCR4 expression
Inflammatory bowel disease (IBD) is characterized by a chronically dysregulated immune response in the gastrointestinal tract. Bone marrow multipotent mesenchymal stromal cells have an important immunomodulatory function and support regeneration of inflamed tissue by secretion of soluble factors as well as through direct local differentiation. CXCR4 is the receptor for CXCL12 (SDF‐1, stromal‐derived factor‐1) and has been shown to be the main chemokine receptor, required for homing of MSCs. Increased expression of CXCL12 by inflamed intestinal tissue causes constitutive inflammation by attracting lymphocytes but can also be used to direct MSCs to sites of injury/inflammation. Trypsin is typically used to dissociate MSCs into single‐cell suspensions but has also been shown to digest surface CXCR4. Here, we assessed the regenerative effects of CXCR4high and CXCR4low MSCs in an immune‐deficient mouse model of DSS‐induced colitis. We found that transplantation of MSCs resulted in clinical improvement and histological recovery of intestinal epithelium. In contrary to our expectations, the levels of CXCR4 on transplanted MSCs did not affect their regenerative supporting potential, indicating that paracrine effects of MSCs may be largely responsible for their regenerative/protective effects.
- Open Access
A pilot study: Nano‐hydroxyapatite‐PEG/PLA containing low dose rhBMP2 stimulates proliferation and osteogenic differentiation of human bone marrow derived mesenchymal stem cells
Background: Bone morphogenetic protein 2 (BMP2) can enhance posterolateral spinal fusion (PLSF). The minimum effective dose that may stimulate mesenchymal stem cells however remains unknown. Nano‐hydroxyapatite (nHAp) polyethylene glycol (PEG)/polylactic acid (PLA) was combined with recombinant human BMP2 (rhBMP2). We in vitro evaluated proliferation, differentiation, and osteogenic genes of human bone marrow mesenchymal stem cells with 0.5, 1.0, and 3.0 μg/mL rhBMP2 doses in this study.Methods: In vitro experimental study was designed to proliferation by a real‐time quantitative cell analysis system and the osteogenic differentiation by alkaline phosphatase (ALP) activity and osteogenic marker (Runx2, OPN, and OCN) gene expressions of human derived bone marrow mesenchymal stem cells (hBMMSCs). nHAp was produced by wet chemical process and characterized by Fourier transform infrared spectrophotometer, scanning electron microscopy, and energy‐dispersive x‐ray spectroscopy. PEG/PLA polymer was produced at a 51:49 molar ratio. 0.5, 1.0, and 3.0 μg/mL rhBMP2 and nHAp was combined with the polymers. hBMMSCs were characterized by multipotency assays and surface markers were assessed by flow cytometer. The hBMMSC‐rhBMP2 containing nHAp‐PEG/PLA composite interaction was evaluated by transmission electron microscopy. Proliferative effect was evaluated by real‐time proliferation analysis, and osteogenic capacity was evaluated by ALP activity assay and qPCR.Results: hBMMSC proliferation in the 0.5 μg/mL rhBMP2 + nHAp‐PEG/PLA and the 1.0 μg/mL rhBMP2 + nHAp‐PEG/PLA groups were higher compared to control. 1.0 μg/mL rhBMP2 + nHAp‐PEG/PLA and 3.0 μg/mL rhBMP2 + nHAp‐PEG/PLA containing composites induced ALP activity on days 3 and 10. 0.5 μg/mL rhBMP2 + nHAp‐PEG/PLA application stimulated Runx2 and OPN gene expressions.Conclusion: rhBMP2 + nHAp‐PEG/PLA composites stimulate hBMMSC proliferation and differentiation. The nHAp‐PEG/PLA composite with low dose of rhBMP2 may enhance bone formation in future clinical PLSF applications.
Open AccessA pilot study: Nano‐hydroxyapatite‐PEG/PLA containing low dose rhBMP2 stimulates proliferation and osteogenic differentiation of human bone marrow derived mesenchymal stem cells
Background: Bone morphogenetic protein 2 (BMP2) can enhance posterolateral spinal fusion (PLSF). The minimum effective dose that may stimulate mesenchymal stem cells however remains unknown. Nano‐hydroxyapatite (nHAp) polyethylene glycol (PEG)/polylactic acid (PLA) was combined with recombinant human BMP2 (rhBMP2). We in vitro evaluated proliferation, differentiation, and osteogenic genes of human bone marrow mesenchymal stem cells with 0.5, 1.0, and 3.0 μg/mL rhBMP2 doses in this study.Methods: In vitro experimental study was designed to proliferation by a real‐time quantitative cell analysis system and the osteogenic differentiation by alkaline phosphatase (ALP) activity and osteogenic marker (Runx2, OPN, and OCN) gene expressions of human derived bone marrow mesenchymal stem cells (hBMMSCs). nHAp was produced by wet chemical process and characterized by Fourier transform infrared spectrophotometer, scanning electron microscopy, and energy‐dispersive x‐ray spectroscopy. PEG/PLA polymer was produced at a 51:49 molar ratio. 0.5, 1.0, and 3.0 μg/mL rhBMP2 and nHAp was combined with the polymers. hBMMSCs were characterized by multipotency assays and surface markers were assessed by flow cytometer. The hBMMSC‐rhBMP2 containing nHAp‐PEG/PLA composite interaction was evaluated by transmission electron microscopy. Proliferative effect was evaluated by real‐time proliferation analysis, and osteogenic capacity was evaluated by ALP activity assay and qPCR.Results: hBMMSC proliferation in the 0.5 μg/mL rhBMP2 + nHAp‐PEG/PLA and the 1.0 μg/mL rhBMP2 + nHAp‐PEG/PLA groups were higher compared to control. 1.0 μg/mL rhBMP2 + nHAp‐PEG/PLA and 3.0 μg/mL rhBMP2 + nHAp‐PEG/PLA containing composites induced ALP activity on days 3 and 10. 0.5 μg/mL rhBMP2 + nHAp‐PEG/PLA application stimulated Runx2 and OPN gene expressions.Conclusion: rhBMP2 + nHAp‐PEG/PLA composites stimulate hBMMSC proliferation and differentiation. The nHAp‐PEG/PLA composite with low dose of rhBMP2 may enhance bone formation in future clinical PLSF applications.
- Open Access
- 11 May 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-16
A pumpless monolayer microfluidic device based on mesenchymal stem cell-conditioned medium promotes neonatal mouse in vitro spermatogenesis
Background: Childhood cancer treatment-induced gonadotoxicity causes permanent infertility/sub-infertility in nearly half of males. The current clinical and experimental approaches are limited to cryopreservation of prepubertal testicular strips and in vitro spermatogenesis which are inadequate to achieve the expanded spermatogonial stem/progenitor cells and spermatogenesis in vitro. Recently, we reported the supportive effect of bone marrow-derived mesenchymal cell co-culture which is inadequate after 14 days of culture in static conditions in prepubertal mouse testis due to lack of microvascular flow and diffusion. Therefore, we generated a novel, pumpless, single polydimethylsiloxane-layered testis-on-chip platform providing a continuous and stabilized microfluidic flow and real-time cellular paracrine contribution of allogeneic bone marrow-derived mesenchymal stem cells. Methods: We aimed to evaluate the efficacy of this new setup in terms of self-renewal of stem/progenitor cells, spermatogenesis and structural and functional maturation of seminiferous tubules in vitro by measuring the number of undifferentiated and differentiating spermatogonia, spermatocytes, spermatids and tubular growth by histochemical, immunohistochemical, flow cytometric and chromatographic techniques. Results: Bone marrow-derived mesenchymal stem cell-based testis-on-chip platform supported the maintenance of SALL4(+) and PLZF(+) spermatogonial stem/progenitor cells, for 42 days. The new setup improved in vitro spermatogenesis in terms of c-Kit(+) differentiating spermatogonia, VASA(+) total germ cells, the meiotic cells including spermatocytes and spermatids and testicular maturation by increasing testosterone concentration and improved tubular growth for 42 days in comparison with hanging drop and non-mesenchymal stem cell control. Conclusions: Future fertility preservation for male pediatric cancer survivors depends on the protection/expansion of spermatogonial stem/progenitor cell pool and induction of in vitro spermatogenesis. Our findings demonstrate that a novel bone marrow-derived mesenchymal stem cell-based microfluidic testis-on-chip device supporting the maintenance of stem cells and spermatogenesis in prepubertal mice in vitro. This new, cell therapy-based microfluidic platform may contribute to a safe, precision-based cell and tissue banking protocols for prepubertal fertility restoration in future.
- 11 May 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-16
Open AccessA pumpless monolayer microfluidic device based on mesenchymal stem cell-conditioned medium promotes neonatal mouse in vitro spermatogenesis
Background: Childhood cancer treatment-induced gonadotoxicity causes permanent infertility/sub-infertility in nearly half of males. The current clinical and experimental approaches are limited to cryopreservation of prepubertal testicular strips and in vitro spermatogenesis which are inadequate to achieve the expanded spermatogonial stem/progenitor cells and spermatogenesis in vitro. Recently, we reported the supportive effect of bone marrow-derived mesenchymal cell co-culture which is inadequate after 14 days of culture in static conditions in prepubertal mouse testis due to lack of microvascular flow and diffusion. Therefore, we generated a novel, pumpless, single polydimethylsiloxane-layered testis-on-chip platform providing a continuous and stabilized microfluidic flow and real-time cellular paracrine contribution of allogeneic bone marrow-derived mesenchymal stem cells. Methods: We aimed to evaluate the efficacy of this new setup in terms of self-renewal of stem/progenitor cells, spermatogenesis and structural and functional maturation of seminiferous tubules in vitro by measuring the number of undifferentiated and differentiating spermatogonia, spermatocytes, spermatids and tubular growth by histochemical, immunohistochemical, flow cytometric and chromatographic techniques. Results: Bone marrow-derived mesenchymal stem cell-based testis-on-chip platform supported the maintenance of SALL4(+) and PLZF(+) spermatogonial stem/progenitor cells, for 42 days. The new setup improved in vitro spermatogenesis in terms of c-Kit(+) differentiating spermatogonia, VASA(+) total germ cells, the meiotic cells including spermatocytes and spermatids and testicular maturation by increasing testosterone concentration and improved tubular growth for 42 days in comparison with hanging drop and non-mesenchymal stem cell control. Conclusions: Future fertility preservation for male pediatric cancer survivors depends on the protection/expansion of spermatogonial stem/progenitor cell pool and induction of in vitro spermatogenesis. Our findings demonstrate that a novel bone marrow-derived mesenchymal stem cell-based microfluidic testis-on-chip device supporting the maintenance of stem cells and spermatogenesis in prepubertal mice in vitro. This new, cell therapy-based microfluidic platform may contribute to a safe, precision-based cell and tissue banking protocols for prepubertal fertility restoration in future.
- Open Access
Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection
Background: Vaccines that incorporate multiple SARS‐CoV‐2 antigens can further broaden the breadth of virus‐specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS‐CoV‐2 VLP vaccine that incorporates the four structural proteins of SARS‐CoV‐2.Methods: VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography, and characterized by tunable‐resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine.Results: Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS‐CoV‐2. Alum adsorbed, K3‐CpG ODN‐adjuvanted VLPs elicited high titer anti‐S, anti‐RBD, anti‐N IgG, triggered multifunctional Th1‐biased T‐cell responses, reduced virus load, and prevented lung pathology upon live virus challenge in vaccinated animals.Conclusion: These data suggest that VLPs expressing all four structural protein antigens of SARS‐CoV‐2 are immunogenic and can protect animals from developing COVID‐19 infection following vaccination.
Open AccessDevelopment and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection
Background: Vaccines that incorporate multiple SARS‐CoV‐2 antigens can further broaden the breadth of virus‐specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS‐CoV‐2 VLP vaccine that incorporates the four structural proteins of SARS‐CoV‐2.Methods: VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography, and characterized by tunable‐resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine.Results: Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS‐CoV‐2. Alum adsorbed, K3‐CpG ODN‐adjuvanted VLPs elicited high titer anti‐S, anti‐RBD, anti‐N IgG, triggered multifunctional Th1‐biased T‐cell responses, reduced virus load, and prevented lung pathology upon live virus challenge in vaccinated animals.Conclusion: These data suggest that VLPs expressing all four structural protein antigens of SARS‐CoV‐2 are immunogenic and can protect animals from developing COVID‐19 infection following vaccination.
- 10 May 2021
- Published by Springer Nature
- p. 269-289
Trace Element Containing Nano-HAp for Preventing Musculoskeletal Infections
- 10 May 2021
- Published by Springer Nature
- p. 269-289
Trace Element Containing Nano-HAp for Preventing Musculoskeletal Infections
- 1 May 2021
- Published by Elsevier in The Spine Journal
- Vol. 21 (5) , 865-873
A novel nano-hydroxyapatite/synthetic polymer/bone morphogenetic protein-2 composite for efficient bone regeneration
- 1 May 2021
- Published by Elsevier in The Spine Journal
- Vol. 21 (5) , 865-873
A novel nano-hydroxyapatite/synthetic polymer/bone morphogenetic protein-2 composite for efficient bone regeneration